Owen Mumford Ltd (Owen Mumford) designs, manufactures, and markets diagnostic equipment and disposables. The company has manufacturing expertise in the development of injection-based drug delivery products, blood sampling equipment, and specialist products. The company offers solutions for therapy areas, including allergy reaction testing, cancer, cholesterol, diabetes, migraine, multiple sclerosis, Parkinson’s, point of care, and rheumatoid arthritis under its own brands and custom device solutions for pharmaceutical and diagnostic companies. The company offers a range of injections and blood sampling products designed to support self-management and treatment programs for various conditions and therapy areas, including diabetes care, eye care and reproductive health.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Owen Mumford has undertaken several R&D initiatives focused on achieving differentiation through innovation. The company has developed a pipeline of development project opportunities to expand its product portfolio and support future growth. Key projects include the Aidaptus device, a two-step autoinjector platform developed in collaboration with the Stevanato Group, and a reusable autoinjector designed to work with the Unisafe syringe. The company is also investing in digital solutions for connected healthcare and sustainable offerings, utilizing lifecycle analysis tools to identify environmental benefits. Additionally, the company is expanding its presence in the blood collection and pelvic healthcare segments.